Navigation Links
ANAVEX reports sigma receptor review published in leading journal
Date:8/27/2009

GENEVA, Switzerland, Aug. 27 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX" or the "Company") (OTCBB: AVXL) reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

The paper provides new insight into sigma-1 receptors and their potential ability to alter the course of Alzheimer's disease, other CNS conditions and cancer. In their review, leading scientists Dr. Tangui Maurice and Dr. Tsung-Ping Su emphasize that sigma-1 receptors effect the modulation of various ion channels, including calcium, potassium, sodium and chloride ions, which allow atoms to enter or leave a cell and change its behavior. Further work may show the impact on mitochondria, a cell's principal energy source. Dysfunction in the mitochondria is a known contributor to neurodegenerative diseases such as Alzheimer's and a wide range of other diseases. ANAVEX believes that mitochondrial dysfunction can be modified using sigma receptors to guard against oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease.

"This review sheds new light on the field of sigma receptors," said Dr. Herve de Kergrohen, CEO of ANAVEX. "ANAVEX is pleased that academic leaders are communicating the hope that this new understanding of mechanisms of action in the field of sigma receptors could bring to a range of conditions. This is particularly relevant to Alzheimer's patients, their families and caregivers."

ANAVEX is the leader in the discovery and development of new drugs that specifically target sigma receptors. The company's lead compound for Alzheimer's disease, ANAVEX 2-73, is being prepared to enter clinical trials in 2010. ANAVEX 2-73 is a selective sigma-1 receptor agonist (Vamvakides, 2002; Espallergues et al., 2007) and has demonstrated potent neuroprotective, anti-amnesic, anti-convulsive and anti-depressive activity in pre-clinical studies.

To read the complete report by Drs Maurice and Su, visit the publications section at www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a global company with headquarters in Switzerland. The company is engaged in the discovery and development of novel drug targets for the treatment of neurological diseases and cancer. ANAVEX's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet medical and market needs and new scientific advances.

ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drugs that target neurological and neurodegenerative diseases, such as Alzheimer's disease, epilepsy, depression, pain and neuropathic pain. The company's lead candidates have shown strong evidence for anti-amnesic and neuroprotective properties in studies conducted to date. ANAVEX believes that mitochondrial dysfunction can be modulated via sigma receptors, a unique class of receptor molecules, to guard against oxidative stress.

ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel drugs targeting cancer. The company's lead candidates have shown strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file an IND or commence clinical studies. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information

Anavex Life Sciences Corp.

Research Business Development

Email: info@anavex.com

Shareholder Media Relations

Toll-free: 1-866-505-2895

Outside North America: +1 (416) 489-0092

Email: ir@anavex.com

www.anavex.com


'/>"/>
SOURCE Anavex Life Sciences Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
2. Consumer Reports Health News - August 2009
3. FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
4. China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results
5. STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM))
6. Weikang Bio-Technology Group Co., Inc. Reports Record Second Quarter Results
7. Cyberonics Reports Strong Fiscal 2010 First Quarter Results
8. Neovasc Inc. Reports Second Quarter 2009 Financial Results
9. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
10. Lilly Reports on Outcome of Phase III Study of Arzoxifene
11. Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a ... select from up to two layers of subject matter along with fully customizable backdrop ... Final Cut Pro X. , With ProSlideshow Portrait each user are given ...
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... **An FDAnews Webinar**, Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... exacting business. It’s easy to get things wrong, run afoul of The Quality ...
(Date:9/21/2017)... Angeles, CA (PRWEB) , ... September 21, 2017 ... ... a lunch and learn with Infinity Behavioral Health Services for professionals in the ... in a Commercial Payer Audit . , Insurance companies and state and ...
(Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)... Sept. 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) ... aural experiences — and deliver these experiences as part of ... people feel and heal better. ... While nothing beats a walk, jog or ... mind, Life Environments™ is the next best thing when getting ...
(Date:8/31/2017)... NEW YORK , Aug. 31, 2017 ... the industry,s must-read guide to the latest innovations happening ... the first industry publication to focus on providing a ... advancements. Ultimately, the issue covers the most innovative companies, ... year. "Everyone in ...
Breaking Medicine Technology: